New drug combo targets Hard-to-Treat prostate cancer
NCT ID NCT07115446
First seen Jan 08, 2026
Summary
This early-stage trial is testing a combination of two experimental drugs, HS-20093 and HRS-5041, in men with advanced prostate cancer that has progressed after standard hormone therapy. HS-20093 is an antibody-drug conjugate that targets a protein on cancer cells, while HRS-5041 breaks down androgen receptors. The study aims to find the safest dose and check for side effects. About 63 men will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-20093 (an antibody-drug conjugate) combined with HRS-5041 (a drug that breaks down androgen receptors)
What this could lead to
If it works, this could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early Phase 1 trial with only 63 participants, so safety and dosing are still being figured out. The combination may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.